Zepatier + Ribavirin + Sofosbuvir
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Hepatitis C
Trial Timeline
Jul 20, 2016 → Jan 1, 2018
NCT ID
NCT02781649About Zepatier + Ribavirin + Sofosbuvir
Zepatier + Ribavirin + Sofosbuvir is a approved stage product being developed by Merck for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02781649. Target conditions include End-Stage Renal Disease, Hepatitis C.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02781649 | Approved | Completed |
Competing Products
20 competing products in End-Stage Renal Disease